We investigated associations between interferon (IFN)-gamma-inducible protein (IP)-10 and liver histological results, viral kinetic response, and treatment outcome in patients infected with hepatitis C virus (HCV) genotypes 1-4.Plasma IP-10 was monitored before, during, and after treatment with pegylated IFN- alpha 2a and ribavirin in 265 HCV-infected patients.In univariate analyses, a low baseline IP-10 level was significantly associated with low baseline viral load, rapid viral response (RVR), a sustained viral response (SVR), body mass index <25 kg/m2, and less-pronounced fibrosis, inflammation, and steatosis (for HCV genotypes other than 3). When the results of the univariate analyses were included in multivariate analyses, a low plasma IP-10 level, low baseline viral load, and genotype 2 or 3 infection were independent predictors of an RVR and SVR. IP-10 levels decreased 6 weeks into treatment and remained low in patients with an SVR. By contrast, plasma levels of IP-10 rebounded in patients who had detectable HCV RNA after the completion of treatment. Using cutoff IP-10 levels of 150 and 600 pg/mL for predicting an SVR in patients infected with HCV genotype 1 yielded a specificity and sensitivity of 81% and 95%, respectively.Baseline IP-10 levels are predictive of the response to HCV treatment.

Original publication




Journal article


The Journal of infectious diseases

Publication Date





895 - 903


Department of Virology, University of Göteborg, Göteborg, Sweden.


DITTO-HCV Study Group, Liver, Humans, Hepacivirus, Hepatitis C, Chronic, Polyethylene Glycols, Interferon-alpha, Recombinant Proteins, RNA, Viral, Ribavirin, Chemokines, CXC, Antiviral Agents, Treatment Outcome, Drug Therapy, Combination, Viral Load, Adult, Middle Aged, Female, Male, Chemokine CXCL10, Interferon-gamma